Direct oral anticoagulant prescribing trends for venous thromboembolism among adult patients with obesity at University of Utah Health

• Published in: Thrombosis research 2025-01, Vol.245, p.109216, Article 109216
• Main Authors: Vandenhazel, Hailey L., Wilson, Aaron S., Ye, Xiangyang, Vazquez, Sara R., Witt, Daniel M.
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Aged; Anticoagulants; Anticoagulants - therapeutic use; Direct-acting oral anticoagulant; Drug prescriptions; Female; Humans; Male; Middle Aged; Obesity; Obesity - complications; Obesity - drug therapy; Retrospective Studies; Utah; Venous Thromboembolism - drug therapy; Warfarin - therapeutic use
• ISSN: 0049-3848; 1879-2472; 1879-2472
• DOI: 10.1016/j.thromres.2024.109216

Anticoagulants, including warfarin and direct oral anticoagulants (DOACs), are used to prevent and treat venous thromboembolism (VTE) which is common in patients with obesity. Guidance statements regarding use of DOACs for VTE treatment in this patient population have been updated. Examine DOAC prescribing trends in patients with obesity and VTE. We performed a retrospective, single-site cross-sequential study of DOAC prescribing trends in adult patients with obesity (BMI ≥30) and objectively confirmed VTE diagnosis between 2014 and 2022. The primary outcome of interest was the proportion of patients with obesity prescribed DOACs. A total of 1826 patients were included in our analysis. Most patients were of White race (85.8 %) and approximately half were female. Pulmonary embolism was the most common VTE type (62.2 %). A total of 1018 patients were prescribed DOAC therapy (55.8 %), 524 warfarin therapy (28.7 %), and 284 enoxaparin (15.6 %). Logistic regression analysis revealed that the utilization of DOACs exhibited a significant upward trend from 2017 to 2022 (odds ratio [OR] 1.85 to 14.08 compared to 2014), but not from 2015 to 2016 (OR 1.30 to 1.52). Patients with BMI ≥ 40 and ≥ 50 were twice and 4-times as likely to be prescribed warfarin than DOACs, respectively. Between 2017 and 2022, the proportion of patients with obesity prescribed DOACs for the treatment of VTE increased significantly. This suggests an increasing likelihood to prescribe DOACs in this patient population despite the lack of safety and efficacy data from randomized controlled trials except for very heavy patients. •Few patients with obesity were included in clinical trials evaluating DOACs for VTE.•Guidance statements providing information about DOAC use in obesity have been updated.•This study showed significant increases in DOAC use for VTE in obesity over time.•Patients with BMI >40 were less likely to be prescribed DOACs vs. warfarin or LMWH.